QQQ   307.50 (+1.29%)
AAPL   154.43 (+1.78%)
MSFT   266.35 (+3.73%)
META   190.44 (+2.35%)
GOOGL   105.37 (+2.40%)
AMZN   100.18 (-1.96%)
TSLA   194.10 (-0.34%)
NVDA   218.26 (+3.49%)
NIO   10.81 (-1.10%)
BABA   104.70 (-0.71%)
AMD   84.53 (+1.02%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.82 (+3.07%)
CGC   2.81 (-4.75%)
GE   81.58 (-0.94%)
DIS   111.15 (+1.17%)
AMC   6.34 (-6.76%)
PFE   43.51 (-0.57%)
PYPL   82.41 (+0.10%)
NFLX   360.60 (-0.24%)
QQQ   307.50 (+1.29%)
AAPL   154.43 (+1.78%)
MSFT   266.35 (+3.73%)
META   190.44 (+2.35%)
GOOGL   105.37 (+2.40%)
AMZN   100.18 (-1.96%)
TSLA   194.10 (-0.34%)
NVDA   218.26 (+3.49%)
NIO   10.81 (-1.10%)
BABA   104.70 (-0.71%)
AMD   84.53 (+1.02%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.82 (+3.07%)
CGC   2.81 (-4.75%)
GE   81.58 (-0.94%)
DIS   111.15 (+1.17%)
AMC   6.34 (-6.76%)
PFE   43.51 (-0.57%)
PYPL   82.41 (+0.10%)
NFLX   360.60 (-0.24%)
QQQ   307.50 (+1.29%)
AAPL   154.43 (+1.78%)
MSFT   266.35 (+3.73%)
META   190.44 (+2.35%)
GOOGL   105.37 (+2.40%)
AMZN   100.18 (-1.96%)
TSLA   194.10 (-0.34%)
NVDA   218.26 (+3.49%)
NIO   10.81 (-1.10%)
BABA   104.70 (-0.71%)
AMD   84.53 (+1.02%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.82 (+3.07%)
CGC   2.81 (-4.75%)
GE   81.58 (-0.94%)
DIS   111.15 (+1.17%)
AMC   6.34 (-6.76%)
PFE   43.51 (-0.57%)
PYPL   82.41 (+0.10%)
NFLX   360.60 (-0.24%)
QQQ   307.50 (+1.29%)
AAPL   154.43 (+1.78%)
MSFT   266.35 (+3.73%)
META   190.44 (+2.35%)
GOOGL   105.37 (+2.40%)
AMZN   100.18 (-1.96%)
TSLA   194.10 (-0.34%)
NVDA   218.26 (+3.49%)
NIO   10.81 (-1.10%)
BABA   104.70 (-0.71%)
AMD   84.53 (+1.02%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.82 (+3.07%)
CGC   2.81 (-4.75%)
GE   81.58 (-0.94%)
DIS   111.15 (+1.17%)
AMC   6.34 (-6.76%)
PFE   43.51 (-0.57%)
PYPL   82.41 (+0.10%)
NFLX   360.60 (-0.24%)
NYSE:BIO

Bio-Rad Laboratories - BIO Stock Forecast, Price & News

$473.94
+4.25 (+0.90%)
(As of 02/7/2023 01:25 PM ET)
Add
Compare
Today's Range
$466.17
$475.36
50-Day Range
$399.55
$480.49
52-Week Range
$344.63
$670.61
Volume
25,820 shs
Average Volume
146,529 shs
Market Capitalization
$14.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$651.25

Bio-Rad Laboratories MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
38.1% Upside
$651.25 Price Target
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.65mentions of Bio-Rad Laboratories in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.45%
From $14.38 to $15.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

114th out of 1,029 stocks

Analytical Instruments Industry

4th out of 28 stocks

BIO stock logo

About Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Analysts Set Bio-Rad Laboratories, Inc. (NYSE:BIO) PT at $651.25
Bio-Rad Laboratories (NYSE:BIO) Trading Up 5.4%
Chromatography Market Latest Research Report 2023-2025
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Company Calendar

Last Earnings
10/28/2021
Today
2/07/2023
Next Earnings (Confirmed)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
09057220
Employees
7,900
Year Founded
1952

Price Target and Rating

Average Stock Price Forecast
$651.25
High Stock Price Forecast
$700.00
Low Stock Price Forecast
$565.00
Forecasted Upside/Downside
+37.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$4.25 billion
Net Margins
-215.16%
Pretax Margin
-279.57%

Debt

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$15.91 per share
Book Value
$456.60 per share

Miscellaneous

Free Float
21,652,000
Market Cap
$14.13 billion
Optionable
Optionable
Beta
0.92

Social Links


Key Executives

  • Norman D. Schwartz
    Chairman, President & Chief Executive Officer
  • Andrew J. Last
    Chief Operating Officer & Executive Vice President
  • Ilan DaskalIlan Daskal
    Chief Financial Officer & Executive Vice President
  • Simon May
    Executive VP & President-Life Science Group
  • Timothy S. ErnstTimothy S. Ernst
    Secretary, Executive VP & General Counsel













BIO Stock - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIO shares.
View BIO analyst ratings
or view top-rated stocks.

What is Bio-Rad Laboratories' stock price forecast for 2023?

4 Wall Street analysts have issued 12 month target prices for Bio-Rad Laboratories' stock. Their BIO share price forecasts range from $565.00 to $700.00. On average, they expect the company's share price to reach $651.25 in the next year. This suggests a possible upside of 38.1% from the stock's current price.
View analysts price targets for BIO
or view top-rated stocks among Wall Street analysts.

How have BIO shares performed in 2023?

Bio-Rad Laboratories' stock was trading at $420.49 at the beginning of the year. Since then, BIO stock has increased by 12.2% and is now trading at $471.69.
View the best growth stocks for 2023 here
.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 252,500 shares, an increase of 8.8% from the December 15th total of 232,100 shares. Based on an average trading volume of 237,400 shares, the short-interest ratio is currently 1.1 days. Currently, 1.2% of the shares of the stock are short sold.
View Bio-Rad Laboratories' Short Interest
.

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our BIO earnings forecast
.

How can I listen to Bio-Rad Laboratories' earnings call?

Bio-Rad Laboratories will be holding an earnings conference call on Thursday, February 16th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings results on Thursday, October, 28th. The medical research company reported $3.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $1.41. The medical research company had revenue of $747 million for the quarter, compared to analyst estimates of $670.36 million. Bio-Rad Laboratories had a negative net margin of 215.16% and a positive trailing twelve-month return on equity of 4.13%. Bio-Rad Laboratories's revenue for the quarter was up 15.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.00 earnings per share.
Read the conference call transcript
.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Veritas Asset Management LLP (3.86%), AustralianSuper Pty Ltd (1.09%), Allspring Global Investments Holdings LLC (0.91%), Fisher Asset Management LLC (0.48%), Ardevora Asset Management LLP (0.38%) and Envestnet Asset Management Inc. (0.35%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Giovanni Magni, Ilan Daskal, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends
.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $471.69.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $14.07 billion and generates $2.92 billion in revenue each year. The medical research company earns $4.25 billion in net income (profit) each year or ($201.80) on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

The company employs 7,900 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?
The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.

This page (NYSE:BIO) was last updated on 2/7/2023 by MarketBeat.com Staff